1. Home
  2. MIR vs NUVL Comparison

MIR vs NUVL Comparison

Compare MIR & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mirion Technologies Inc.

MIR

Mirion Technologies Inc.

HOLD

Current Price

$24.53

Market Cap

6.0B

Sector

Technology

ML Signal

HOLD

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$104.32

Market Cap

7.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MIR
NUVL
Founded
2005
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.0B
7.1B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
MIR
NUVL
Price
$24.53
$104.32
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
14
Target Price
$28.29
$134.29
AVG Volume (30 Days)
3.3M
828.0K
Earning Date
10-28-2025
10-30-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.10
N/A
Revenue
$902,300,000.00
N/A
Revenue This Year
$8.15
N/A
Revenue Next Year
$19.02
N/A
P/E Ratio
$243.04
N/A
Revenue Growth
7.82
N/A
52 Week Low
$12.00
$55.54
52 Week High
$30.28
$112.88

Technical Indicators

Market Signals
Indicator
MIR
NUVL
Relative Strength Index (RSI) 46.51 52.26
Support Level $24.52 $103.83
Resistance Level $26.36 $107.99
Average True Range (ATR) 1.03 3.38
MACD 0.02 -0.87
Stochastic Oscillator 31.93 12.44

Price Performance

Historical Comparison
MIR
NUVL

About MIR Mirion Technologies Inc.

Mirion Technologies Inc provides products, services, and software that allow customers to safely leverage the power of ionizing radiation for applications that benefit the health, safety, vitality, and technological progress of the human experience. The Company manages its operations through two segments: Nuclear & Safety and Medical. The Medical segment improves the quality and safety of cancer care delivery and supports applications across medical diagnostics and practitioner safety. The Nuclear & Safety segment powers advancements in nuclear energy and critical radiation safety, measurement and analysis applications across laboratories, research and other industrial markets such as defense.

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Share on Social Networks: